AlphAIAlphAI — Financial news for AI agents
investing.comNOV 32 min read$AMGN

Amgen beats third quarter forecasts on top and bottom lines

Amgen (AMGN) reported Q3 earnings of $6.45 per share, beating estimates by $0.69, with revenue up 8% YoY to $10.4B. The company raised 2026 guidance, but some products faced biosimilar competition. Growth drivers included UPLIZNA, TEZSPIRE, and Repatha. Free cash flow was $3.7B, down from $4.2B YoY.

Original reporting
investing.com
Published Nov 3, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AMGN
Bullish
high confidence
Mentioned
$AMGN
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The earnings beat and raised guidance could trigger short covering and new buying, especially in biotech‑focused funds.

02

Market read

The report provides fresh, material data that can drive immediate trading decisions on AMGN.

03

What to watch

Biosimilar competition pressure on Prolia and XGEVA could weigh on margins.

Relevance 9/10Novelty 9/10Timing: post‑market reaction today

Background

Amgen is a leading biotech firm with a diversified portfolio; its quarterly results are closely watched.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen reported Q3 earnings beat and raised FY2026 revenue and EPS guidance above consensus.

Expected impact

likely upward pressure as investors price in the beat and higher guidance

Evidence & confidence

The company posted adjusted EPS $6.45 vs $5.76 estimate and raised revenue guidance to $38.9‑$39.7B, indicating stronger performance.

Market effects

Sector

Biotech sector may see broader optimism from Amgen's strong results.

Regional

U.S. large‑cap biotech stocks could rally in response.

Global

Amgen's guidance influences global pharma investors tracking US biotech earnings.

Counterpoint

What could challenge this read

Some analysts may caution that free cash flow fell year‑over‑year, tempering upside.

Key entities

  • company
    Amgen Inc.

    Biopharmaceutical company reporting Q3 results.

Read at source← All news

StoryAmgen posts Q3 2026 earnings beat and lifts 2026 revenue and EPS outlook

Also covered by

5 outlets

Related articles

NOV 4
$AMGNLow

Amgen starts MariTide autoinjector study as pivotal readouts approach

Amgen (AMGN) is advancing its GLP-1 drug candidate, MariTide, with a new Phase 3 study for autoinjector use, aiming for a 2027 completion. The company expects pivotal Phase 3 data next year, with dosing frequency and tolerability as key focus areas. Amgen plans $2.6B in capital expenditures this year, partly for MariTide manufacturing. Q3 revenues rose 8% to $10.4B, with strong performance from key brands.

biospace.com1 min
NOV 4
$AMGNMed

Amgen stock price target raised to $531 by TD Cowen on growth

TD Cowen raised its price target on Amgen (AMGN) to $531 from $452, citing strong Q3 2026 results and growth prospects. The stock trades near its 52-week high. Amgen's revenue and EPS guidance were increased, driven by products like Uplizna and Imdelltra. Multiple analysts revised earnings upwards, though the stock is slightly overvalued according to InvestingPro.

investing.com2 min
NOV 4
$AMGNMedAI 8/10

Truist raises Amgen stock price target on earnings beat

Truist Securities raised its price target for Amgen (AMGN) to $398 from $380, maintaining a Hold rating. The stock is near its 52-week high after Q3 2026 earnings beat expectations, with revenue of $10.4B and EPS of $6.45. Amgen raised full-year revenue and EPS guidance. Analysts cite strong performance and pipeline potential as key drivers.

investing.com2 min